Document is current
Any future updates will be listed below
-
Authors
Zhao, Manlin
Chen, Yang
Li, Mingxiao
Jiang, Chao
Wang, Zhen
Liu, Hongyu
He, Liu
Sang, Caihua
Du, Xin
Dong, Jianzeng
Packer, Douglas L.
Ma, Changsheng
Lip, Gregory Y. H.
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2022YFC3601303)
National Natural Science Foundation of China (82270316)
- License Information
-
More Information
Article History
Received: 13 August 2025
Accepted: 2 January 2026
First Online: 12 January 2026
Declarations
:
: This analysis was waived for ethical approval by the University of Liverpool Research Integrity and Ethics (Reference 15107). Patient consent was not required for this secondary data analysis.
: Not applicable.
: GYHL is a consultant and speaker for Bristol Myers Squibb/Pfizer, Boehringer Ingelheim, Anthos, and Daiichi Sankyo; no fees personally. Dr Lip is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 899871. CSM has received honoraria for presentations from AstraZeneca, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, and Pfizer. JZD has received honoraria for presentations from Johnson & Johnson. All other authors declare no competing interests.
